Journal article icon

Journal article

Low risk of recurrence following artesunate-Sulphadoxine-pyrimethamine plus primaquine for uncomplicated Plasmodium falciparum and Plasmodium vivax infections in the Republic of the Sudan

Abstract:

Background

First-line schizontocidal treatment for uncomplicated malaria in the Republic of the Sudan is artesunate (total dose 12 mg/kg) plus Sulphadoxine/pyrimethamine (25/1.25 mg/kg) (AS/SP). Patients with Plasmodium vivax are also treated with 14 days primaquine (total dose 3.5 mg/kg) (PQ). The aim of this study was to assess the efficacy of the national policy.

Methods

Patients above 1 year, with microscopy-confirmed, Plasmodium falciparum and/or P. vivax mal...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed
Version:
Publisher's version

Actions


Access Document


Files:
Publisher copy:
10.1186/s12936-018-2266-9

Authors


Hamid, MMA More by this author
Thriemer, K More by this author
Elobied, ME More by this author
Mahgoub, NS More by this author
Boshara, SA More by this author
Expand authors...
Bill and Melinda Gates Foundation More from this funder
the Australian Department of Foreign Affairs and Trade More from this funder
More from this funder
Grant:
Senior Fellowship in Clinical Science, 200909
Publisher:
BioMed Central Publisher's website
Journal:
Malaria Journal Journal website
Volume:
17
Issue:
1
Pages:
117
Publication date:
2018-03-05
Acceptance date:
2018-03-08
DOI:
EISSN:
1475-2875
Pubs id:
pubs:831391
URN:
uri:c7918e8f-3819-4370-b480-e2bf71e9f234
UUID:
uuid:c7918e8f-3819-4370-b480-e2bf71e9f234
Local pid:
pubs:831391
Language:
English
Keywords:

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP